Experimental lung cancer vaccine trial halted early
NCT ID NCT04432207
First seen Mar 26, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment aimed to help the immune system fight cancer, given alone or with other drugs. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cabrini Malvern Hospital
Melbourne, Victoria, 3000, Australia
-
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Macquarie University
Macquarie, New South Wales, 2109, Australia
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.